

Clinical Differences in Triple-Positive Breast Cancer Subtype

Supplementary Table 1. Baseline characteristics of patients included in the data registry of the Seoul St. Mary's Hospital of the Catholic Medical Center

Characteristic	Subtype				p-value
	Triple-positive (n=169) No. (%)	Luminal A (n=724) No. (%)	HER2-enriched (n=206) No. (%)	Luminal B with HER2(-) (n=668) No. (%)	
Age at diagnosis (yr)					<0.001
<40	26 (15.4)	64 (8.8)	19 (9.2)	81 (12.1)	
40-49	66 (39.1)	252 (34.8)	42 (20.4)	241 (36.1)	
50-59	44 (26.0)	232 (32.0)	102 (49.5)	200 (29.9)	
≥60	33 (19.5)	176 (24.2)	43 (20.9)	146 (21.9)	
BMI (kg/m ²)					0.389
<18.5	8 (4.7)	29 (4.0)	5 (2.4)	24 (3.6)	
18.5-22.9	83 (49.1)	326 (45.0)	81 (39.3)	274 (41.0)	
23-24.9	37 (21.9)	166 (22.9)	50 (24.3)	155 (23.2)	
≥25	41 (24.3)	203 (28.0)	70 (34.0)	215 (32.2)	
pT stage					<0.001
T1	91 (53.8)	528 (72.9)	104 (50.5)	390 (58.4)	
T2	67 (39.6)	165 (22.8)	82 (39.8)	248 (37.1)	
T3	8 (4.7)	25 (3.5)	16 (7.8)	25 (3.7)	
T4	3 (1.8)	3 (0.4)	2 (1.0)	2 (0.3)	
Tis	0	3 (0.4)	2 (1.0)	1 (0.1)	
pN stage					0.002
N0	97 (57.4)	512 (70.7)	117 (56.8)	445 (66.6)	
N1	45 (26.6)	151 (20.9)	58 (28.2)	162 (24.3)	
N2	15 (8.9)	43 (5.9)	18 (8.7)	35 (5.2)	
N3	12 (7.1)	18 (2.5)	13 (6.3)	26 (3.9)	
TNM stage					<0.001
I	64 (37.9)	418 (57.7)	75 (36.4)	307 (46.0)	
II	76 (45.0)	232 (32.0)	95 (46.1)	293 (43.9)	
III	29 (17.2)	74 (10.2)	36 (17.5)	68 (10.2)	
EGFR					<0.001
Negative	135 (86.0)	638 (90.0)	102 (51.5)	553 (83.8)	
Positive	22 (14.0)	71 (10.0)	96 (48.5)	107 (16.2)	
Recurrence	11 (6.5)	29 (4.0)	22 (10.7)	42 (6.3)	0.001
Follow-up duration (mo)*	36.79±23.97	39.49±21.57	35.95±20.33	31.18±20.66	0.001 [†]

HER2=human epidermal growth factor receptor 2; BMI=body mass index; EGFR=epidermal growth factor receptor.

*Mean±SD; [†]One way ANOVA.